Freshfields Bruckhaus Deringer LLP (‘Freshfields’) has advised Helios Health on its acquisition of the Eugin Group from NMC Health, through the acquisition of a majority stake (and potentially 100 per cent) in the Spanish company, Luarmia, S.L.U., and of 100 per cent of the stake of NMC Eugin US Corporation, at a combined valuation of EUR 430m.
Helios Health is a German company, holding of the Fresenius-Helios private hospital and clinics business segment, which includes the business of Helios in Germany and the business of Quirónsalud in Spain and Latam. The acquisition will enable Helios to expand its healthcare international footprint in the IVF sector.
Completion of the transaction is subject to a number of regulatory approvals and is expected to happen in H1 2021.
The Freshfields team advising on the deal was led in Spain by partner Javier Monzón and in the US by partners John Fisher (Silicon Valley) and Paul Humphreys (New York), supported by lead associates Lucía Quiroga (Madrid) and David Chen (Silicon Valley).